Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT


1Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK
2Department of Medical Physics and Clinical Engineering, Nottingham University Hospitals NHS Trust, Nottingham, UK
3The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK
4Whipps Cross Hospital and The Royal London Hospital, Barts Health NHS Trust, London, UK
5Blackheath Hospital, Winchester House, London, UK
6Nottingham Clinical Trials Unit, Nottingham, UK
7Leicester Royal Infirmary, Leicester, UK
8York Hospital, York Teaching Hospital NHS Foundation Trust, York, UK
9Medical School, Newcastle University, Newcastle upon Tyne, UK
10Royal Derby Hospital and the London Road Community Hospital, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
11Solihull Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
12Cannock Chase Hospital and New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK
13Division of Infection and Immunity, Cardiff University, Cardiff, UK
14Chelsea and Westminster Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
15Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
16West Glasgow Ambulatory Care Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK

*Corresponding author Kim.Thomas@Nottingham.ac.uk
†Joint first authors
‡The full author list can be found in Appendix 1.
Declared competing interests of authors: Anthony Bewley reports personal fees from AbbVie Inc. (North Chicago, IL, USA), Almirall SA (Barcelona, Spain), Leo Pharma (Ballerup, Denmark), Galderma SA (Lausanne, Switzerland), Janssen Pharmaceutica (Beerse, Belgium), Novartis Pharmaceuticals (Basel, Switzerland), Eli Lilly and Company (Indianapolis, IN, USA), and Thornton and Ross Ltd (Huddersfield, UK) during the conduct of the study. Lelia Duley reports grants from the NIHR Clinical Trials Unit support funding during the conduct of the study. Robert Ellis reports personal fees from AMLo Biosciences Ltd (Newcastle upon Tyne, UK) and AbbVie Inc. outside the submitted work. Adam Ferguson reports non-financial support from the National Institute for Health Research (NIHR) during the conduct of the study. John Ingram reports personal fees from UCB Pharma (Brussels, Belgium), Novartis Pharmaceuticals and AbbVie Inc. outside the submitted work. Tracey H Sach was a member of the NIHR Health Technology Assessment (HTA) Commissioning Board (September 2017–January 2020), a member of the NIHR HTA General Funding Board (November 2016–September 2017) and a core member of the NIHR HTA Themed Calls Funding Board (2013–2016). Shyamal Wahie reports non-financial support from Janssen Pharmaceutica, AbbVie Inc., Novartis Pharmaceuticals and Almirall SA outside the submitted work. Hywel C Williams is Director of the HTA programme and chairperson of the HTA Commissioning Board (September 2015–October 2020). From 1 January 2016 he became Programme Director for the HTA programme. He reports grants from NIHR HTA during the conduct of the study and is a member of the HTA Clinical Evaluation and Trials Committee, although he had no role in the decision to fund this study. Alan A Montgomery reports grants from NIHR (Infrastructure Award CTU-26 and NIHR132545) during the conduct of the study.

Disclaimer: This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

Published November 2020
DOI: 10.3310/hta24640

Scientific summary

HI-Light Vitiligo three-arm RCT
Health Technology Assessment 2020; Vol. 24: No. 64
DOI: 10.3310/hta24640

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Vitiligo is a skin condition that results in complete loss of pigment. It affects around 0.5–2% of the world’s population and can develop at any age. Vitiligo can be distressing for patients, especially when it occurs on exposed areas, such as the face and hands.

Current clinical guidelines for the management of vitiligo recommend topical corticosteroids, narrowband ultraviolet B light, topical tacrolimus and combination treatments, but the evidence base for all treatment approaches is limited.

The Home Interventions and Light therapy for the treatment of vitiligo (HI-Light Vitiligo) trial addresses two priority topics from a James Lind Alliance Priority Setting Partnership that were highlighted as being important to people with vitiligo and health-care professionals:

1. Which treatment is more effective for vitiligo – steroid creams/ointments or light therapy?
2. How effective is ultraviolet B light therapy when combined with creams or ointments in treating vitiligo?

Objectives

1. To evaluate the comparative effectiveness and safety of home-based interventions for the management of active, limited vitiligo in adults and children. Comparing:

   - hand-held narrowband ultraviolet B light with potent topical corticosteroids [mometasone furoate 0.1% ointment (Elocon®, Merck Sharp & Dohme Corp., Merck & Co., Inc., Whitehouse Station, NJ, USA)]
   - combination of hand-held narrowband ultraviolet B light plus potent topical corticosteroids with potent topical corticosteroids alone.

2. To assess whether or not treatment response (if any) is maintained once the interventions are stopped.
3. To compare the cost-effectiveness of the interventions from an NHS and, separately, a family perspective.
4. To understand the barriers to and facilitators of adoption of these interventions in the UK NHS.

Methods

Study design

A multicentre, three-arm, parallel-group, pragmatic, placebo-controlled randomised controlled trial, with nested health economic analysis and process evaluation.

Recruitment and follow-up

Participants were recruited from 16 UK hospitals, with recruitment from primary care, secondary care and community advertising, and were trained to deliver the treatments in their homes.
Treatment was for 9 months with a further 12-month follow-up; participants attended hospital clinics on 2 consecutive days at baseline for recruitment and training, and then at 3, 6 and 9 months to assess outcomes. Follow-up to 21 months was carried out using 3-monthly questionnaires.

**Eligibility criteria**
Participants were aged ≥ 5 years, with a diagnosis of non-segmental vitiligo, limited to approximately ≤ 10% of body surface area, and at least one vitiligo patch that had been active in the last 12 months (self-reported). Participants had to be willing to stop other vitiligo therapies, able to follow the treatment instructions and comply with safety precautions at home, and willing and able to give informed (or parental/carer) consent.

Participants were excluded if they:

- had segmental or universal vitiligo
- had vitiligo limited solely to areas contraindicated for treatment with potent topical corticosteroids
- had a history of skin cancer, radiotherapy use or photosensitivity (based on minimum erythemal dose test)
- had an allergy or contraindication to mometasone furoate
- were pregnant, breastfeeding or likely to become pregnant during the trial
- were on immunosuppressive drugs
- were involved in another clinical trial.

Participants could also be excluded if an investigator thought that they were unable to use the treatments safely.

**Interventions**
Participants received a hand-held narrowband ultraviolet B light unit (active or dummy) and either topical corticosteroids (mometasone furoate 0.1% ointment) or placebo ointment (vehicle). Treatments were used for up to 9 months. Participants received face-to-face training, online training and a written handbook of instructions.

At baseline, participants selected a target patch that had been active in the last 12 months and in which they most wanted to see improvement. Participants could select up to two further study patches for treatment, with a maximum of one on each of three anatomical regions (head and neck, hands and feet, and rest of the body). Participants could treat additional patches if they wished, but these were not assessed in the study.

Hand-held narrowband ultraviolet B light (Dermfix 1000 MX, Dermfix Limited, Chalfont St Giles, UK) was used on alternate days. The treatment schedule had a starting dose of 0.05 J/cm² and increased incrementally. Participants recorded treatment times and side effects in a participant diary.

Topical corticosteroids or placebo ointment was applied once daily on alternate weeks (i.e. 1 week on, 1 week off).

**Outcomes**

**Primary outcome**
Treatment success at the target patch of vitiligo after 9 months of treatment was measured using the participant-reported Vitiligo Noticeability Scale. Treatment success was defined as vitiligo being 'a lot less noticeable' or 'no longer noticeable' compared with before treatment.
Secondary outcomes

- Blinded assessment of treatment success (using Vitiligo Noticeability Scale) at the target patch by a panel of three blinded assessors with vitiligo using digital images at baseline and 9 months.
- Participant-reported treatment success for each of the three body regions using the Vitiligo Noticeability Scale, assessed at 9 months (all assessed patches).
- Onset of treatment response at the target patch: assessed by investigators using the question ‘Compared with the start of the study, has there been a change in the vitiligo patch?’ Onset of treatment response was defined as ‘stayed the same (i.e. not worsened)’ or ‘improved’ as all target patches were active patches at baseline.
- Percentage repigmentation: for the target patch at 9 months, using digital images assessed by a clinician unaware of treatment allocation (treatment success ≥ 75% repigmentation), plus blinded assessment by investigators at 3, 6 and 9 months.
- Vitiligo-specific and generic quality of life: assessed at end of treatment (9 months) and end of follow-up (21 months).
- Maintenance of treatment response: assessed by participants for the target patch of vitiligo at 12, 15, 18 and 21 months post randomisation, using the question ‘Compared to since you stopped using the study treatments, has there been a change in the vitiligo patch?’ Loss of treatment response was defined as a response of ‘worse’ at any time point.
- Burden of treatment: time per session for active light treatment and participant-reported treatment burden for topical corticosteroids and light treatments at 3, 6 or 9 months.

Safety outcomes

Adverse reactions during the treatment phase were recorded. Events of interest were predefined as grade 3 or 4 erythema and skin thinning. All serious adverse events were also recorded.

Sample size

The target sample size was 440 participants (assuming 15% of participants allocated to topical corticosteroids alone would achieve treatment success, and to detect a clinically significant absolute difference between groups of 20%, with 2.5% two-sided alpha, 90% power and 15% loss to follow-up). A planned sample size review by the Data Monitoring Committee after 18 months of recruitment recommended extending recruitment to 516 participants.

Randomisation and blinding

Participants were randomised to active topical corticosteroids plus dummy narrowband ultraviolet B light (topical corticosteroids-only group); active narrowband ultraviolet B light plus placebo ointment (narrowband ultraviolet B light-only group); or active topical corticosteroids ointment plus active narrowband ultraviolet B light (combination group). Randomisation was minimised by recruiting centre, body region of target patch (head and neck, hands and feet, or rest of the body) and age (5–15 years or ≥ 16 years). Randomisation was via a secure web server created and maintained by the Nottingham Clinical Trials Unit to ensure allocation concealment. A central pharmacy distributed the interventions directly to participants’ homes.

Participants, research nurses, principal investigators, members of trial management group and data analysts were blinded to treatment allocation. Owing to the unblinding risk from skin erythema after narrowband ultraviolet B light treatment, additional outcome assessments were performed by a panel
of three patient assessors (for the primary analysis) and a blinded clinician for the secondary outcome of percentage repigmentation, using digital images taken at baseline and at 9 months.

**Statistical methods**

For all analyses, two prespecified between-group comparisons were made: narrowband ultraviolet B light versus topical corticosteroids, and narrowband ultraviolet B light plus topical corticosteroids versus topical corticosteroids.

Primary analysis was by intention to treat and with multiple imputation of missing data. The number and percentage of participants achieving ‘treatment success’ was reported. Randomised groups were compared using a mixed-effects model for binary outcomes, adjusted by recruitment centre, body region of target patch and age at randomisation. The primary estimate of effect was the difference in the percentage of participants achieving treatment success at 9 months, with 95% confidence intervals and \( p \)-values. We also reported relative differences using risk ratios. Sensitivity analyses were conducted to (1) adjust for any variables with imbalance at baseline, (2) repeat primary analysis based on participants with primary outcome data and (3) investigate the impact that treatment adherence had on the results. Planned subgroup analyses were (1) children versus adults; (2) body region of the target vitiligo patch; (3) hypomelanotic patch (an indicator of disease activity), definitely or maybe versus no; and (4) \( \geq 4 \) years duration of vitiligo versus < 4 years. It is thought that patches that are hypomelanotic, with poorly defined borders, are more likely to be active patches, and therefore more responsive to treatment. Patches were assessed at the point of randomisation using a Wood’s lamp, and designated as hypomelanotic with poorly defined borders (or ‘hypomelanotic’ for short) or amelanotic with sharply defined borders. These analyses were conducted by inclusion of appropriate interaction terms in the regression model and were considered as exploratory. An additional post hoc subgroup analysis explored the impact of skin type (types I–III vs. types IV–VI).

Secondary outcomes were analysed by a similar approach, using appropriate regression modelling depending on outcome type.

**Health economics**

A nested health economic analysis explored cost-effectiveness of the interventions from an NHS perspective (primary) and a family perspective (secondary). These were assessed using participant self-report of health-care appointments (number, which professional and relevance to vitiligo), prescriptions for vitiligo treatments and personal expenses. The base-case analysis estimates an incremental cost per additional successful treatment with incremental cost per quality-adjusted life-year presented in the secondary analyses.

**Process evaluation**

A mixed-methods process evaluation study was conducted to inform the interpretation of trial results and to explore barriers to and facilitators of adoption of the interventions in the UK NHS.

A total of 25 trial participants (adults, young people or parents) and 10 commissioners were interviewed (nine interviews), 24 recruiting site staff completed an online survey and 13 site staff participated in study-review focus groups.

Interviews and focus group data were analysed thematically using an inductive approach; descriptive statistics were generated for online survey responses. Interview prompts and analysis were informed
by an initial programme theory, which proposed how combination treatment might ideally work in the NHS. Data were organised to address three key questions:

1. Is home-based treatment manageable for people with vitiligo?
2. Should combination treatment be made more widely available?
3. Could combination treatment be made more widely available in the NHS?

Results

Between May 2016 and September 2017, 517 participants were randomised (adults, \( n = 398 \); children, \( n = 119 \)). Primary outcome data were available for 370 (72%) participants. Baseline characteristics were well balanced.

The median percentage of narrowband ultraviolet B light treatment-days was 81% for topical corticosteroids, 77% for narrowband ultraviolet B light and 74% for combination groups, and for ointment 79% for topical corticosteroids, 83% for narrowband ultraviolet B light and 77% for combination. Just under half of the participants used the treatments for > 75% of the expected duration.

Investigators thought that they had become unblinded for 21%, 28% and 27% of the participants in the topical corticosteroids, narrowband ultraviolet B light and combination groups, respectively. The percentages of participants who thought that they had become unblinded were 39%, 55% and 44%, respectively. Unblinding guesses for narrowband ultraviolet B light were correct approximately 80% of the time, but for topical corticosteroids the guesses were correct less than half of the time.

For the primary outcome, treatment success using the Vitiligo Noticeability Scale at 9 months was reported by 20 out of 119 (17%) of those allocated topical corticosteroids, 27 out of 123 (22%) of those allocated narrowband ultraviolet B light and 34 out of 128 (27%) of those allocated combination treatment. The adjusted risk difference between combination treatment and topical corticosteroids was 10.9% (95% confidence interval 1.0% to 20.9%; \( p = 0.03 \)) and for narrowband ultraviolet B light compared with topical corticosteroids was 5.2% (95% confidence interval –4.4% to 14.9%; \( p = 0.29 \)). Corresponding adjusted risk ratios were 1.93 (95% confidence interval 1.02 to 3.68) for combination treatment compared with topical corticosteroids and 1.44 (95% confidence interval 0.77 to 2.70) for narrowband ultraviolet B light compared with topical corticosteroids.

Participants who adhered to \( \geq 75\% \) of expected treatments were more likely to achieve treatment success in the combination group compared with topical corticosteroids (adjusted odds ratio 2.73, 95% confidence interval 1.24 to 6.02), but not for ultraviolet B light compared with topical corticosteroids (adjusted odds ratio 1.52, 95% confidence interval 0.56 to 4.11).

Secondary outcomes supported the primary analysis. Treatment success (Vitiligo Noticeability Scale) based on assessment of digital images by patient reviewers showed similar results but were more likely to suggest benefit from narrowband ultraviolet B light, with evidence of differences in treatment success for both the narrowband ultraviolet B light and the combination groups, compared with the topical corticosteroids group.

Percentage repigmentation success rates (\( \geq 75\% \) repigmentation), using blinded assessment of digital images, confirmed that combination treatment was better than topical corticosteroids: 4 out of 119 (3%) for the topical corticosteroids group, 9 out of 123 (8%) for narrowband ultraviolet B light group and 18 out of 128 (15%) for the combination group.
Quality of life was high at baseline for all groups and showed no between-group differences at 9 or 21 months post randomisation.

Overall, 94% of participants achieved onset of treatment response by 3 months for all groups (defined as the active target patch having improved or stayed the same, i.e. not worsened): topical corticosteroids (40% improved, 57% stayed the same); narrowband ultraviolet B light (61% improved, 35% stayed the same); or combination (60% improved, 38% stayed the same).

For participants using active light devices the median treatment time was 20 minutes per treatment session. Participants required just over 1 hour (mean 70 minutes) of face-to-face training prior to using the treatment at home.

Burden of treatment was identified as an issue by 42 out of 142 (30%) participants in the topical corticosteroids group, 38 out of 140 (27%) in the narrowband ultraviolet B light group and 36 out of 149 (24%) in the combination group, although interpretation is difficult as all three groups used both treatments throughout (either active or dummy/placebo). In general, narrowband ultraviolet B light treatment was more burdensome than treatment with topical corticosteroids.

Grade 3 or 4 erythema occurred in 62 (12%) participants (three using dummy), and transient skin thinning occurred in 13 (2.5%) participants (two using placebo), with no serious adverse treatment effects.

In line with the clinical results, the primary cost-effectiveness analysis showed that the unadjusted incremental cost per additional successful treatment was £2328.56 (adjusted £1932.35) for combination treatment compared with topical corticosteroids alone and £4801.92 (adjusted £3335.74) for narrowband ultraviolet B light alone compared with topical corticosteroids alone. Whether or not combination treatment is considered to offer value for money to the NHS depends on the maximum willingness to pay of decision-makers to gain an additional treatment success, and there is currently no evidence as to what the level might be.

**Process evaluation findings**

Process evaluation findings suggest that stakeholders were positive about the role of combination treatment in the management of vitiligo.

Despite being time-consuming and (potentially) complex, both participants and health-care professionals indicated that, with appropriate support, combination treatment could be managed at home. Appropriate training and ongoing monitoring, particularly in the early stages of treatment are essential, especially given the concerns about potential side effects associated with the treatments.

Trial participants and health-care professionals both advocated the broader use of combination treatment in the NHS, with some caveats about which patients might benefit most.

Both health-care professionals and commissioners recognised that the need for a developed infrastructure (i.e. nursing support, medical physics service) might be a barrier to broader NHS provision. Regional clinics might be a possible solution, as may some form of mixed economy approach, where patients purchase light therapy devices alongside NHS support and training.
Conclusions

Implications for health care
Combination treatment with narrowband ultraviolet B light and potent topical corticosteroids is superior to potent topical corticosteroids alone, although the benefits are likely to be modest. Combination treatment was relatively safe, well tolerated and could be considered cost-effective for people with limited vitiligo that had been active within the last 12 months.

Home-based narrowband ultraviolet B light therapy requires quality control of devices, training and support from health-care professionals with experience of delivering phototherapy services and is time intensive for patients. However, home-based narrowband ultraviolet B light therapy appears to be a useful treatment option for people with localised active vitiligo and provides considerable advantages over hospital narrowband ultraviolet B light therapy, which requires hospital visits two or three times per week.

Use of mometasone furoate 0.1% (a potent corticosteroid) as first-line treatment for vitiligo is supported as it achieved treatment success in one in six individuals and was effective in stopping the spread of active vitiligo patches. It was also found to be safe in both adults and children when used daily on alternate weeks for 9 months.

Treatment effects were lost once interventions were stopped, suggesting that intermittent maintenance therapy is likely to be needed.

These findings require a broad dissemination strategy that includes general practice as well as dermatology services.

Implications for research
Research priorities include:

1. development and testing of new vitiligo treatments with a greater response and longer-lasting effects
2. investigation of treatments suitable for people with widespread vitiligo
3. research into different strategies to maintain treatment response once treatments are stopped
4. further development and validation of outcome instruments to be included in the vitiligo core outcome set, to facilitate combining of trial results in meta-analyses.

Trial registration

This trial is registered as ISRCTN17160087.

Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 64. See the NIHR Journals Library website for further project information.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 12/24/02. The contractual start date was in November 2014. The draft report began editorial review in September 2019 and was accepted for publication in May 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. This report has been published following a shortened production process and, therefore, did not undergo the usual number of proof stages and opportunities for correction. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2020. This work was produced by Batchelor et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijn Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk